Navigation Links
Keryx Biopharmaceuticals Settles License Dispute With Alfa Wassermann
Date:8/4/2009

NEW YORK, Aug. 4 /PRNewswire-FirstCall / -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) announced today that the Company and Alfa Wassermann S.p.A. have settled a dispute over issues arising from the terminated license agreement for Sulonex (sulodexide). Under the terms of the settlement agreement, Alfa Wassermann is paying Keryx US$3,500,000 (of which US$2,750,000 has already been received by Keryx and $750,000 is to be paid to Keryx on or before July 30, 2010), and Keryx shall deliver to Alfa Wassermann all of its data, information and other intellectual property related to Sulonex.

Ron Bentsur, Chief Executive Officer of Keryx, stated, "We are pleased that this matter has been resolved in a manner that we believe serves the best interests of the Keryx shareholders. This settlement provides us with additional non-dilutive cash to move our compounds into Phase 3 trials."

ABOUT KERYX BIOPHARMACEUTICALS, INC.

Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, including renal disease and cancer. Keryx is developing Zerenex((TM)) (ferric citrate), an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. Zerenex has recently completed a Phase 2 clinical program as a treatment for hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease. Keryx is also developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that inhibits the phosphoinositide 3-kinase (PI3K)/Akt pathway, a key signaling cascade that has been shown to induce cell growth and cell transformation. KRX-0401 has demonstrated both safety and clinical efficacy in numerou
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Keryx Biopharmaceuticals Announces Agreement with FDA on a Special Protocol Assessment for Phase 3 Trial of KRX-0401 (Perifosine) in the Treatment of Multiple Myeloma
2. Keryx Biopharmaceuticals Inc. Regains Compliance With NASDAQ Listing Requirements
3. Keryx Biopharmaceuticals, Inc. Receives Extension for Nasdaq Listing Compliance
4. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2009 Financial Results
5. Keryx Biopharmaceuticals, Inc. Requests an Appeal Hearing After Receiving Notice of Delisting From Nasdaq
6. Keryx Biopharmaceuticals Receives Nasdaq Notification
7. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2008 Financial Results
8. Keryx Biopharmaceuticals KRX-0401 (Perifosine) Data Selected for Oral Presentation at the 50th Annual Meeting of the American Society of Hematology
9. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2008 Financial Results on Tuesday, November 11, at 8:30 A.M. EST
10. Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2008 Financial Results
11. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) to be Presented at the Upcoming American Society of Hematology Meeting in Atlanta, Georgia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/2/2015)... Beach, FL (PRWEB) May 02, 2015 ... has selected The Delray Recovery Center as one of ... Center is known in the addiction treatment field for ... staff members to innovate and to continue their educational ... a positive workplace environment, never forgetting their purpose – ...
(Date:5/2/2015)... ZoomCare, the Portland-based innovator of on-demand healthcare ... its new healthcare insurance to individuals and small businesses ... System is the nation’s first health insurance system built ... Personal Health Insurance was ZoomCare’s first such filing including ... to review and regulation by the Oregon Insurance Division. ...
(Date:5/1/2015)... Jusuru International has been awarded the prestigious ... its flagship nutritional supplement, Liquid BioCell™ Life, and the ... new logo, new packaging, new products, and new messaging. ... identify and promote programs that serve as examples of ... Jusuru International for their outstanding accomplishments and contributions to ...
(Date:5/1/2015)... 2015 Hope For The Warriors® thanks ... For The Warriors® and military families. All American Ford ... For The Warriors®, a national nonprofit dedicated to restoring ... restoring hope for our service members and our military ... Ford collected and matched small autograph fee from fans ...
(Date:5/1/2015)... Colorado (PRWEB) May 01, 2015 As ... States approaches its 18-month anniversary, many people in the ... been achieved. , According the latest annual report by ... expanded 74 percent in 2014, and reached nearly $3 ... America’s decades-long love affair with cannabis, combined with the ...
Breaking Medicine News(10 mins):Health News:The Delray Recovery Center Named 2015 Top Workplace 2Health News:ZoomCare Applies to be on Oregon Exchange 2Health News:Jusuru International Receives 2015 DSA Ethos Award 2Health News:Jusuru International Receives 2015 DSA Ethos Award 3Health News:Jusuru International Receives 2015 DSA Ethos Award 4Health News:Jusuru International Receives 2015 DSA Ethos Award 5Health News:All American Ford Presents Donation to Nonprofit Hope For The Warriors 2Health News:Colorado cannabis dispensary owner credits employees for successful “420” retail sales figures 2Health News:Colorado cannabis dispensary owner credits employees for successful “420” retail sales figures 3
... Feb. 12 Bunker Hill Community College is ... held a series of events on National Wear Red Day ... disease is the leading cause of death in women. Stickers ... campaign - were handed out to the entire College community, ...
... Feb. 12 Medicare now pays for treatments deemed ... that and apply a cost-effectiveness standard set by a ... Research.The Federal Council is modeled after a U.K. board ... This British board approves or rejects treatments using a ...
... as likely to show early damage, and study says it,s likely ... who consume two or more cans of soda pop daily are ... evidence of kidney disease, according to a U.S. study. , But ... pop or for people who drink diet soda. , The researchers ...
... Slumdog Millionaire show the challenges facing the polio eradication ... Oscar-watchers are getting a short course in polio eradication ... show the status of this paralyzing disease in India ... virus has not been stopped. The Final Inch, ...
... ISTA ), today announced it will release fourth quarter and ... a conference call to discuss these results and provide a pipeline ... Date: Thursday, February 19, 2009, ... Internet: www.istavision.com, Domestic dial-in: 866-730-5766, ...
... who as children got radiation treatment for Hodgkin,s disease are ... cancer, according to findings from five institutions, including the University ... higher the risk, researchers report. These women are also likely ... is always to get rid of the cancer. Our second ...
Cached Medicine News:Health News:Bunker Hill Community College Celebrates 'Wear Red Day' 2Health News:2 or More Sodas a Day Boost Women's Kidney Risks 2Health News:Oscar Nominated Films Raise Polio Awareness 2Health News:Pediatric Hodgkin's disease survivors face increased breast cancer risk 2Health News:Pediatric Hodgkin's disease survivors face increased breast cancer risk 3
(Date:4/30/2015)... April 30, 2015  Thoratec Corporation (NASDAQ: THOR ... to save, support and restore failing hearts, said today ... Lynch 2015 Healthcare Conference on Thursday, May 14. ... Executive Officer, will provide an update on the company, ... Eastern Daylight Time). The presentation will be ...
(Date:4/30/2015)... -- DURECT Corporation (Nasdaq: DRRX ) announced today financial ... were $4.8 million and net loss was $4.9 million ... compared to total revenues of $6.3 million and net ... March 31, 2014.At March 31, 2015, we had cash ... investments of $34.9 million at December 31, 2014.  Subsequent ...
(Date:4/30/2015)... Company plc (NYSE: PRGO ; TASE) today announced that Perrigo ... at the 2015 Deutsche Bank 40 th Annual Healthcare Conference ... Hotel in Boston , MA.  ... Joseph C. Papa will present at the Bank of America ... 12, 2015 at the Encore at Wynn Las Vegas Hotel in ...
Breaking Medicine Technology:Thoratec Presentation At Bank Of America Merrill Lynch Healthcare Conference To Be Webcast 2DURECT Corporation Announces First Quarter 2015 Financial Results and Update of Programs 2DURECT Corporation Announces First Quarter 2015 Financial Results and Update of Programs 3DURECT Corporation Announces First Quarter 2015 Financial Results and Update of Programs 4DURECT Corporation Announces First Quarter 2015 Financial Results and Update of Programs 5DURECT Corporation Announces First Quarter 2015 Financial Results and Update of Programs 6DURECT Corporation Announces First Quarter 2015 Financial Results and Update of Programs 7DURECT Corporation Announces First Quarter 2015 Financial Results and Update of Programs 8DURECT Corporation Announces First Quarter 2015 Financial Results and Update of Programs 9Perrigo Company To Present At Upcoming Healthcare Conferences 2Perrigo Company To Present At Upcoming Healthcare Conferences 3
... - Results Presented at Endocrine Society,s 90th Annual ... June 16 ,Bionovo Inc. (Nasdaq: BNVI ) ... elements important in developing drugs for breast cancer ... Endocrine Society,s,90th Annual Meeting, showed that the new ...
... Metabolex, Inc., a,biopharmaceutical company focused on the ... treatment of metabolic diseases,announced today that it has ... MBX-8025 in overweight or obese patients with high ... designed to assess the drug,s,effect on dyslipidemia and ...
Cached Medicine Technology:Bionovo Discovers New Estrogen Regulatory Elements for Breast Cancer and Osteoporosis Drugs 2Bionovo Discovers New Estrogen Regulatory Elements for Breast Cancer and Osteoporosis Drugs 3Metabolex Completes Patient Enrollment in Phase 2 Trial of MBX-8025 for Treatment of Dyslipidemia 2
Otoscope with 4X magnification lens, swivellable to both sides, with removable cover glass to insert external instruments. Sealed system allowing for pneumatic otoscopy. 2.5V halogen source....
Designed for instrumentation under magnification. Both lens and speculum can be swivelled. Open construction to allow access and examination under magnification and illumination....
Pocket-sized instrument, powered by two AA-sized alkaline batteries. Built-in throat illuminator, rectangular viewing lens for instrumentation under magnification....
Provides 30% more magnification and twice the field of view. Adjustable focus....
Medicine Products: